We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Bladder Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Guru Sonpavde
Nov 15, 2020
Answers to questions:
1. In absence of trial, I would institute docetaxel (without enthusiasm).
2. In presence of FGFR2/3 activating genomic alteration, I would have administered erdafitinib as second-line therapy when patient recurred after radical cystectomy (before pembrolizumab).
3. With current data, no adjuvant therapy is proven, but CHECKMATE274 data are eagerly awaited (Nivolumab improved DFS in all-comers and PD-L1+ patients according to press release).
4. Current optimal systemic therapy for CNS metastases is unclear. Currently, I advise controlling CNS lesions with palliative radiation and institute systemic therapy immediately thereafter.
5. Estimated survival is dismal with CNS metastases (probably worse than liver metastasis, a known poor prognostic factor).
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Daniel
E.
Lage
MD, MSc
Guru Sonpavde
Nov 15, 2020
Apr 19, 2024
Pending Moderator approval.